TO THE EDITOR: We would like to comment on the letter from Seban et al. to the editor of The Journal of Nuclear Medicine in the July issue ([1][1]). The results from the DESTINY-Breast04 trial, receiving a standing ovation during the presidential symposium at the annual conference of the American
No takes yet. Share an insight, caveat, or question.
Altena et al. (2023) studied this question.